Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867845 | 0.79 | TSHR (0.45) | ALDH1A1MAPTTSHRPOLBTDP1 | |
| SCHEMBL23084726 | 0.69 | BTK (0.53) | BTKALDH1A1MAPTTSHRPOLB | |
| SCHEMBL21448744 | 0.69 | BTK (0.53) | BTKALDH1A1MAPTTSHRPOLB | |
| SCHEMBL30672379 | 0.69 | BTK (0.53) | BTKALDH1A1MAPTTSHRPOLB | |
| SCHEMBL13099512 | 0.69 | BTK (0.53) | BTKALDH1A1MAPTTSHRPOLB | |
| SCHEMBL7403095 | 0.68 | CHRM2 (0.35) | OPRM1 | |
| SCHEMBL10904860 | 0.67 | TSHR (0.48) | BTKALDH1A1MAPTTSHRPOLB | |
| SCHEMBL10640944 | 0.66 | KDM4E (0.53) | BTKALDH1A1MAPTTSHRPOLB | |
| SCHEMBL27887609 | 0.66 | BTK (0.50) | BTKALDH1A1MAPTTSHRPOLB | |
| SCHEMBL10904853 | 0.66 | ALDH1A1 (0.46) | BTKALDH1A1MAPTTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | claimed |
| EP-1507765-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INST BIOLOG RES (IL) | 2006-11-02 | — | — | EP | claimed |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISREAL INSTITUTE FOR BIOLOGICAL RESEARCH (US) | 2006-03-09 | — | — | US | claimed |
| CN-1662506-A | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INST BIOLOG RES (IL) | 2005-08-31 | — | — | CN | claimed |
| EP-1507765-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2005-02-23 | — | — | EP | claimed |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2004-03-04 | — | — | US | claimed |
| WO-2003092580-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2003-11-13 | — | — | WO | claimed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-7439251-B2 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2008-10-21 | — | — | US | disclosed |
| US-7049321-B2 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2006-05-23 | — | — | US | disclosed |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISREAL INSTITUTE FOR BIOLOGICAL RESEARCH (US) | 2006-03-09 | — | — | US | disclosed |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | PMP22, PYGB, GAP43 | BTK 2203/4885ALDH1A1 1781/4885MAPT 788/4885 |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | PMP22, PYGB, GAP43 | BTK 2635/4885ALDH1A1 1324/4885MAPT 812/4885 |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | PMP22, PYGB, GAP43 | BTK 2203/4885ALDH1A1 1781/4885MAPT 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.